• Monthly Archives: May 2010

    Anticonvulsants and Bone Loss

    Anticonvulsants are not only used for the treatment of epilepsy but are now used with increasing frequency for the treatment of mood disorders, such as bipolar disorder.  Recent studies have indicated that anticonvulsants may negatively affect bone mineral density, as well as increase fracture risk.  This seems to be especially common with the older anticonvulsants (e.g., phenobarbital, carbamazepine, phenytoin, and valproate); however, the data regarding lamotrigine and other newer anticonvulsants is much more limited.  While bone loss is more often seen with long-term use of these medications, several reports indicate that decreased bone density may also be detected within the first 1-5 years of use.

    By |2015-08-12T16:39:48-04:00May 18th, 2010|General|2 Comments

    Lithium and Breastfeeding

    Bipolar disorder (types I and II) affect up to 5% of the population in the United States. As the onset of this condition typically occurs during or before the reproductive years, the management of bipolar disorder in women is often complicated by pregnancy. There are concerns regarding fetal exposure to medication, the impact of untreated maternal illness, and data demonstrating that women are at increased risk for relapse during the postpartum period.

    New Oral Contraceptive Approved

    The US Food and Drug Administration (FDA) has approved a combination oral contraceptive (OC) tablet called Natazia (Bayer HealthCare Pharmaceuticals).  It is a bit different from other OC preparations in that it contains 4 progestin/estrogen dosing combinations during each 28-day cycle (instead of being monophasic or triphasic), and it contains estradiol valerate (instead of ethinyl estradiol).

    By |2015-08-12T16:36:46-04:00May 12th, 2010|General|0 Comments
    Go to Top